---
title: "Hemogenyx Shares Jump 26% After Securing US Manufacturing Deal for Leukaemia Therapy"
publisher: "Share Talk"
author: "sharetalk"
published: "2025-09-08T11:05:10+00:00"
modified: "2025-09-08T11:05:10+00:00"
date: 2025-09-08
canonical: "https://www.share-talk.com/hemogenyx-shares-jump-26-after-securing-us-manufacturing-deal-for-leukaemia-therapy/"
category: "Health"
categories: ["Health", "Healthcare", "Pharmaceutical"]
image: "https://i0.wp.com/www.share-talk.com/wp-content/uploads/2024/02/HEMO-16_2_24.webp?fit=1200%2C800&quality=80&ssl=1"
format: "news"
language: "en-GB"
---

# Hemogenyx Shares Jump 26% After Securing US Manufacturing Deal for Leukaemia Therapy

**Published:** September 8, 2025
**Author:** sharetalk
**Categories:** Health, Healthcare, Pharmaceutical
**Featured image:** ![](https://i0.wp.com/www.share-talk.com/wp-content/uploads/2024/02/HEMO-16_2_24.webp?fit=1200%2C800&quality=80&ssl=1)

---

**Hemogenyx Pharmaceuticals PLC (LSE: HEMO, OTC: HOPHF)** saw its shares surge **26% on Monday** after announcing a **strategic manufacturing partnership** to advance its **experimental CAR-T therapy, HG-CT-1**, for **acute myeloid leukaemia (AML)**.

The London-listed biotech has partnered with **Made Scientific**, a **US-based contract manufacturer** specialising in **cell therapies**, to **scale up production of HG-CT-1**. The therapy is currently in **early-stage clinical trials** for adults with **relapsed or treatment-resistant AML**.

Under the agreement, **Made Scientific** will oversee **technology transfer and manufacturing** at its **New Jersey facilities**, which are equipped to handle both **clinical and potential commercial supply**.

Hemogenyx said the deal is expected to **accelerate its Phase I trial** and may support the **future inclusion of paediatric patients**.

Chief executive **Vladislav Sandler** described the partnership as pivotal, stating that Made Scientific’s expertise would be *“instrumental in driving the continued progress of this potentially breakthrough therapy.”*

The company added that **early trial data** have shown **promising safety and efficacy signals**.

---

**Original URL:** https://www.share-talk.com/hemogenyx-shares-jump-26-after-securing-us-manufacturing-deal-for-leukaemia-therapy/
*Created by [WP Markdown Endpoint](https://wpmarkdownendpoint.com/)*